RMS Regrow to launch orthopaedic and wound healing theraform in India

Regenerative Medical Services (RMS) Regrow, a cell therapy service provider focusing on orthopaedic and wound healing segments, is planning to launch a bio derived atelocollagen suitable for reconstruction of human tissue in wound management, in collaboration with its strategy partner, the Korea-based Sewon Cellontech.
Theraform, a sterile, pliable, porous surgical wound dressing made of highly purified type I atelocollagen derived from porcine skin is intended for the management of wound care including partial and full-thickness wounds, various ulcers, surgical wounds, trauma wounds and draining wounds. The company is finalising the cost of the product and dealers for the marketing network and is expected to launch the product in a couple of months in India.

Theraform is a bio collagen, which is an absorbable atelocollagen implant for soft tissue regeneration agent. The product could address the partial and full-thickness wounds and also the oral wounds by augmentation in mucosal defects and around implants placed in extraction sockets, alveolar ridge reconstruction, and guided tissue regeneration in periodontal defects and intrabony defects.

The company is conducting studies to integrate usage of Ossron, an autologous bone regeneration therapy, with atelocollagen as part of expanding its operations to the area of regenplasty. Further plans to optimise the use of Ossron in india, by extending the usage to treat osteoporotic fractures mainly affecting the women in postmenopausal age. RMS regrow is also conducting studies on another existing product, Chondron, an autologus cartilage regeneration therapy to expand its use in other therapeutic areas.